JP2022527176A5 - - Google Patents
Info
- Publication number
- JP2022527176A5 JP2022527176A5 JP2021557633A JP2021557633A JP2022527176A5 JP 2022527176 A5 JP2022527176 A5 JP 2022527176A5 JP 2021557633 A JP2021557633 A JP 2021557633A JP 2021557633 A JP2021557633 A JP 2021557633A JP 2022527176 A5 JP2022527176 A5 JP 2022527176A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- compound
- independently
- mannose
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824853P | 2019-03-27 | 2019-03-27 | |
| US62/824,853 | 2019-03-27 | ||
| PCT/US2020/025326 WO2020198622A1 (en) | 2019-03-27 | 2020-03-27 | Compositions and methods for altering macrophage phenotype |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527176A JP2022527176A (ja) | 2022-05-31 |
| JP2022527176A5 true JP2022527176A5 (https=) | 2023-04-03 |
| JP7665206B2 JP7665206B2 (ja) | 2025-04-21 |
Family
ID=72606452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557633A Active JP7665206B2 (ja) | 2019-03-27 | 2020-03-27 | マクロファージの表現型を改変するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11590236B2 (https=) |
| EP (1) | EP3946473A4 (https=) |
| JP (1) | JP7665206B2 (https=) |
| BR (1) | BR112021019187A2 (https=) |
| CA (1) | CA3134974A1 (https=) |
| IL (1) | IL286678B2 (https=) |
| MX (1) | MX2021011703A (https=) |
| WO (1) | WO2020198622A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021019187A2 (pt) * | 2019-03-27 | 2021-12-21 | Navidea Biopharmaceuticals Inc | Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1 |
| US20210052639A1 (en) * | 2019-08-19 | 2021-02-25 | Navidea Biopharmaceuticals, Inc. | Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells |
| JP2025517414A (ja) * | 2022-05-20 | 2025-06-05 | ナビディア、バイオファーマスーティカルズ、インコーポレイテッド | 分解性リンカーを介して新規ビスホスホネート薬物ペイロードを担持するｃｄ２０６標的化薬物送達ビヒクル |
| WO2024076988A2 (en) * | 2022-10-03 | 2024-04-11 | Navidea Biopharmaceuticals, Inc. | Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers |
| CN116259757B (zh) * | 2023-02-06 | 2026-01-30 | 西北大学 | MXene改性的金属离子预嵌入V5O12·6H2O复合材料及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218367B1 (en) * | 1998-09-15 | 2001-04-17 | Organomed Corporation | Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations |
| CN101801462A (zh) | 2007-07-13 | 2010-08-11 | 健泰科生物技术公司 | 用于癌症、炎性病症和自身免疫性病症的治疗和诊断 |
| WO2013057281A2 (en) | 2011-10-21 | 2013-04-25 | Transgene Sa | Modulation of macrophage activation |
| CN114377143A (zh) * | 2013-07-22 | 2022-04-22 | 康德乐健康414有限责任公司 | 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 |
| CA2955438C (en) | 2014-07-17 | 2024-07-02 | Ohio State Innovation Foundation | DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR |
| US10806803B2 (en) * | 2014-07-17 | 2020-10-20 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis |
| WO2016011419A1 (en) * | 2014-07-17 | 2016-01-21 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis |
| WO2016118188A1 (en) * | 2015-01-21 | 2016-07-28 | Navidea Biopharmaceuticals, Inc. | Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells |
| MX2019004029A (es) * | 2016-10-07 | 2019-09-27 | Navidea Biopharmaceuticals Inc | Compuestos y metodos para diagnosis y tratamiento de infecciones virales. |
| EP3522899A4 (en) * | 2016-10-07 | 2020-05-06 | Navidea Biopharmaceuticals, Inc. | Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same |
| CA3064277A1 (en) | 2017-05-19 | 2018-11-22 | Navidea Biopharmaceuticals, Inc. | Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans |
| US20210000920A1 (en) * | 2017-12-22 | 2021-01-07 | Atossa Therapeutics, Inc. | Intraductal methods of treatment of breast disorders |
| BR112021019187A2 (pt) * | 2019-03-27 | 2021-12-21 | Navidea Biopharmaceuticals Inc | Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1 |
| US20210052639A1 (en) * | 2019-08-19 | 2021-02-25 | Navidea Biopharmaceuticals, Inc. | Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells |
-
2020
- 2020-03-27 BR BR112021019187A patent/BR112021019187A2/pt unknown
- 2020-03-27 WO PCT/US2020/025326 patent/WO2020198622A1/en not_active Ceased
- 2020-03-27 JP JP2021557633A patent/JP7665206B2/ja active Active
- 2020-03-27 CA CA3134974A patent/CA3134974A1/en active Pending
- 2020-03-27 MX MX2021011703A patent/MX2021011703A/es unknown
- 2020-03-27 EP EP20779897.6A patent/EP3946473A4/en active Pending
- 2020-03-27 IL IL286678A patent/IL286678B2/en unknown
- 2020-03-27 US US16/832,620 patent/US11590236B2/en active Active
-
2023
- 2023-02-27 US US18/174,783 patent/US20230218770A1/en not_active Abandoned
-
2025
- 2025-07-03 US US19/259,342 patent/US20250325681A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527176A5 (https=) | ||
| Kemp et al. | Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. | |
| JP2020536845A5 (https=) | ||
| JP2020536847A5 (https=) | ||
| JP2020164547A5 (https=) | ||
| JP2023502929A5 (https=) | ||
| JP2021519076A5 (https=) | ||
| JP2017518304A5 (https=) | ||
| JP2021505540A5 (https=) | ||
| JP2017031160A5 (https=) | ||
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| NO20074025L (no) | Konjugater for dobbel billeddannelse og radiokjemoterapi:sammensetninger, fremstilling og anvendelse | |
| Finianos et al. | Zoledronic acid for the treatment of prostate cancer | |
| JP2012509889A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| JP2025501978A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| JP2017506640A5 (https=) | ||
| MX2021011703A (es) | Composiciones y métodos para alterar el fenotipo de macrófagos. | |
| JP2022513684A5 (https=) | ||
| JP2019509986A (ja) | トリプトライドのグルコース・コンジュゲート、その類縁体及び使用 | |
| WO2023114871A8 (en) | Use of combination therapy for treating cancer | |
| EP2683737A1 (en) | Extracellular targeted drug conjugates | |
| JP2021523158A5 (https=) | ||
| JP2022537269A5 (https=) |